Decrease in late presentation for HIV care in Kinshasa, DRC, 2006-2020.
HIV care
Kinshasa
Late presentation
Journal
AIDS research and therapy
ISSN: 1742-6405
Titre abrégé: AIDS Res Ther
Pays: England
ID NLM: 101237921
Informations de publication
Date de publication:
16 07 2021
16 07 2021
Historique:
received:
20
04
2021
accepted:
07
07
2021
entrez:
17
7
2021
pubmed:
18
7
2021
medline:
18
9
2021
Statut:
epublish
Résumé
Late presentation for HIV care is a well-described issue for the success of ART outcomes and the cause of higher morbidity, mortality and further transmission. Monitoring the level of late presentation and understanding the factors associated with it would help to tailor screening and information strategies for better efficiency. We performed a retrospective cohort study in Kinshasa, the capital of the DRC. The studied population included HIV-positive adults newly enrolled in HIV care between January 2006 and June 2020 at 25 HIV urban care facilities. Patient information collected at presentation for HIV care included age, sex, WHO clinical stage and screening context. We used 2 definitions of late presentation: the WHO definition of advanced HIV disease (WHO stage 3/4 or CD4 cell count < 200 cells/mm A total of 10,137 HIV-infected individuals were included in the analysis. The median age was 40 years; 68% were female. A total of 45.9% or 47.5% of the patients were late presenters, depending on the definition used. The percentage of patients with late presentation (defined as WHO stage 3/4 or CD4 cell count < 350 cells/mm The frequency of late presentation for care is decreasing in Kinshasa, DRC. Efforts have to be continued. In particular, the issue of late diagnosis in older individuals should be addressed.
Identifiants
pubmed: 34271957
doi: 10.1186/s12981-021-00366-8
pii: 10.1186/s12981-021-00366-8
pmc: PMC8283988
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
41Informations de copyright
© 2021. The Author(s).
Références
PLoS One. 2017 Mar 30;12(3):e0173928
pubmed: 28358828
Lancet HIV. 2018 Apr;5(4):e172-e180
pubmed: 29352723
N Engl J Med. 2015 Aug 27;373(9):795-807
pubmed: 26192873
BMC Public Health. 2016 Aug 25;16(1):878
pubmed: 27557878
HIV Med. 2019 Feb;20(2):110-120
pubmed: 30430742
BMC Infect Dis. 2016 Apr 29;16:189
pubmed: 27129591
BMC Infect Dis. 2019 Jun 17;19(1):534
pubmed: 31208360
Swiss Med Wkly. 2016 Aug 21;146:w14348
pubmed: 27544642
AIDS. 2021 Apr 1;35(5):841-843
pubmed: 33369905
Sci Rep. 2018 Jun 5;8(1):8594
pubmed: 29872068
AIDS. 2020 Dec 1;34(15):2223-2230
pubmed: 32694412
PLoS One. 2019 Oct 4;14(10):e0223411
pubmed: 31584992
HIV Med. 2011 Jan;12(1):61-4
pubmed: 20561080
Viruses. 2020 Apr 27;12(5):
pubmed: 32349381
Lancet. 2019 Jun 15;393(10189):2428-2438
pubmed: 31056293
Front Microbiol. 2020 Jan 24;10:3060
pubmed: 32038533
PLoS One. 2017 Oct 30;12(10):e0186835
pubmed: 29084276
Clin Infect Dis. 2009 Feb 1;48(3):350-61
pubmed: 19123865
AIDS Res Ther. 2011 Feb 28;8:8
pubmed: 21356115
Nature. 2015 Jan 15;517(7534):381-5
pubmed: 25561180
PLoS One. 2019 Apr 10;14(4):e0214739
pubmed: 30969987
AIDS Res Hum Retroviruses. 2018 Feb;34(2):129-131
pubmed: 28797184